SCHEMBL13115487

SCHEMBL13115487

Cc1ccc(-c2nc(CC(=O)O)c(-c3cccs3)o2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.52
ALDH1A1 P00352 11/20 0.50
NPC1 O15118 4/20 0.50
RAB9A P51151 3/20 0.50
NFKB1 P19838 2/20 0.50
NFKB2 Q00653 2/20 0.50
RELA Q04206 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
TP53 P04637 3/20 0.45
LMNA P02545 1/20 0.45
MAPK1 P28482 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
HPGD P15428 3/20 0.45
POLB P06746 1/20 0.45
XBP1 P17861 1/20 0.45
MAPT P10636 5/20 0.42
HSD17B10 Q99714 2/20 0.42
PPARG P37231 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11077690 0.88 RAB9A (0.48) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL13115597 0.88 KDM4E (0.47) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL13115880 0.87 KDM4E (0.46) KDM4EALDH1A1NPC1RAB9ANFKB1
SCHEMBL13115486 0.87 KDM4E (0.51) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL13116103 0.87 KDM4E (0.49) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL13115601 0.86 ALDH1A1 (0.46) KDM4EALDH1A1NPC1RAB9ANFKB1
SCHEMBL13116100 0.86 KDM4E (0.44) KDM4EALDH1A1SMN1; SMN2LMNAMEN1
SCHEMBL13115791 0.83 KDM4E (0.69) KDM4EALDH1A1NPC1RAB9ANFKB1
SCHEMBL13115803 0.83 ALDH1A1 (0.43) KDM4EALDH1A1NPC1LMNAMEN1
SCHEMBL13115604 0.83 KDM4E (0.53) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256165-A1 LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER HONGU MITSUYA 2010-10-07 US disclosed
US-20100256165-A1 LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER HONGU MITSUYA 2010-10-07 US disclosed
US-7759373-B2 Large conductance calcium-activated K channel opener MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-07-20 US disclosed
US-7759373-B2 Large conductance calcium-activated K channel opener MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256165-A1 LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER KCNN3, KCNN2, KCNN1 KDM4E 801/4885ALDH1A1 4600/4885NPC1 1736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.